[Changes of the blood kallikrein-kinin system in patients with diffuse toxic goiter under the influence of thyrostatic therapy and prodectin].
The author demonstrates absence of normalizing effect of the traditional thyrostatic therapy on the state of the kallikrein-kinin system of the blood, the activity of which rises in diffuse toxic goiter. It was established that the specific antagonist of bradykinin--prodectin (pyridinolcarbamate) proved effective in the correction of the above changes of kininogenesis.
Matiashina
G I
GI
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D007705:Kinins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011727:Pyridinolcarbamate / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013956:Antithyroid Agents; D002219:Carbamates; D007705:Kinins; D011727:Pyridinolcarbamate; D007610:Kallikreins
Izmenenie kallikrein-kininovoĭ sistemy krovi bol'nykh diffuznym toksicheskim zobom pod vliianiem tireostaticheskoĭ terapii i prodektina.